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Background. Hepatolithiasis is highly prevalent in East Asia characterized by the presence of gallstones in the biliary ducts of the
liver. Surgical resection is the potentially curative treatment but bears a high risk of stone recurrence and biliary restenosis. This is
closely related to the universal presence of chronic proliferative cholangitis (CPC) in the majority of patients. Recent evidence
has indicated the association of bacterial infection with the development of CPC in hepatolithiasis. Thus, this study aims to
investigate the feasibility and efficacy of local infusion of gentamicin (an antibiotic) for the treatment of CPC in a rabbit model.
Methods. The rabbit CPC model was established based on previously published protocols. Bile duct samples were collected from
gentamicin-treated or control animals for pathological and molecular characterization. Results. Histologically, the hyperplasia of
biliary epithelium and submucosal glands were inhibited and the thickness of the bile duct wall was significantly decreased after
gentamicin therapy. Consistently, the percentage of proliferating cells marked by ki67 was significantly reduced by the treatment.
More importantly, this treatment inhibited interleukin 2 production, an essential inflammatory cytokine, and the enzyme activity
of endogenous 𝛽-Glucuronidase, a key factor in the formation of bile pigment. Conclusions. Local gentamicin infusion effectively
inhibits the inflammation, cell proliferation, and lithogenesis in a rabbit model of CPC. This approach represents a potential
treatment for CPC and thus prevents recurrent hepatolithiasis.
1. Introduction
Hepatolithiasis, the presence of gallstones in the biliary ducts
of the liver, is a common disease in Asia with incidence
rates ranging from 2% to 25% [1, 2]. It is recognized as an
intractable disease because of the high reoperation rates and a
well-known etiology of cholangiocarcinoma [3–5]. However,
the exact etiology of hepatolithiasis is not clear [6].
Current therapeutic strategies for hepatolithiasis are sur-
gical and nonsurgical treatments. Hepatectomy has been
considered the potentially curative treatment for some cases,
because it can eradicate the stones and the associated
pathologic changes, including biliary stricture, fibrosis, and
microabscess. However, it is more refractory to surgical
treatment than most other benign diseases of the biliary
tract. On the other hand, 42% to 75% biliary stricture
rates were found in hepatolithiasis patients who underwent
hepatectomy [7–12]. In these regards, hepatolithiasis is hardly
curable and its long-term outcome is far from satisfactory.
Chronic proliferative cholangitis (CPC) plays an impor-
tant role in the pathogenesis of stone recurrence and stricture
information. A previous study has reported that bacteria are
present in the bile of all hepatolithiasis patients and Gram-
negative bacteria are the most abundant [13]. Thus, bacterial
infection is thought to be the main cause of CPC. However,
CPC in hepatolithiasis is currently persistent and refractory
to routine antibiotics because of the abnormal organizational
structure in the bile duct wall. Briefly, under the influence of
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infiltration of inflammatory cells and proliferation of fibrous
connective tissue, the peribiliary glands are usually enclosed
to form intricate branches and the blood vessels around these
glands are stenosed or obstructed [14–16].
Gentamicin has been demonstrated to be very sensitive
for most Gram-negative bacteria. It has been applied for
treating wound infection, acute conjunctivitis, and urinary
tract infection by local infusion [17–22].Thus, we hypothesize
that gentamicin might be effective in treating CPC via biliary
infusion. Because medication through biliary infusion could
directly function on the bile duct wall avoiding systematic
side effects. Furthermore, antibiotics could remove the bac-
teria in the submucosa through penetration, regardless of
the stenosis or obstruction of the blood vessels around the
peribiliary glands. In these regards, we intended to investigate
the feasibility and effects of local gentamicin infusion onCPC
in rabbit models, aiming at developing a novel approach to
treat CPC to prevent recurrent hepatolithiasis.
2. Materials and Methods
2.1. Animals and Study Design. Thirty-eight New Zealand
white rabbits weighing 2-3 kg were purchased from the
Experimental Animal Center of Sichuan University and were
randomly divided into three groups: proliferative cholangitis
group (PC group, n=16); antibiotic therapy group (AT, n=16);
sham-operated group (SO group, n=6). The animal model
of CPC was generated for PC and AT groups as previously
described [23, 24]. Briefly, the rabbit’s duodenal wall was
puncturedwith a 26-gauge needle and then a 5-0 nylon thread
was inserted into the commonbile duct through the duodenal
papilla. After the other side of the thread was fixed at the
duodenal wall with a purse-string suture, it was left in the
bile duct for 6 weeks. Then, a polyethylene tube was inserted
into the common bile duct via an incision (about 1mm). The
tube was fixed on the common bile duct wall and 5ml of
saline solution was injected into the tube to prove no leakage.
Finally, the other side of the tube was pulled out through
the abdominal wall and fixed. Biliary infusion with 20ml
gentamicin solution (80,000 units) was performed (once
daily) during the 6 weeks following surgery in the AT group.
For the PC group, 20ml normal saline was a replacement
of antibiotic. For the SO group, only surgical dissection of
common bile duct was performed. After six weeks, all the
rabbits were sacrificed and the common bile ducts and stones
in the ducts were collected for further analysis.
2.2. Histological Examination. Part of the collected bile
duct sample of each rabbit was fixed in formalin (10%
neutral buffered). Four-micrometer sections from paraffin-
embedded tissues were stainedwith hematoxylin-eosin (HE).
The thickness of the bile duct was measured at four points
(two diagonal lines meeting at a 90 angle) along the bile duct
and the mean value was calculated.
2.3. Immunohistochemistry. The tissue sections were incu-
bated with the anti-ki67 primary antibody (Abcam plc Co.,
USA) overnight at 4∘C, followed by incubation with the
biotinylated secondary antibody for 1 hour at 37∘C. The
labeling index (LI) values of Ki-67 were evaluated by digital
image analysis.
2.4. Western Blot. The Cox-2 protein expression in the
common bile duct wall was detected by western blot as
previously described [25] and semiquantitative analysis was
performed by Image-Pro plus 6.0.
2.5. Enzyme Assay. Endogenous and exogenous 𝛽-glucu-
ronidase (𝛽-G) activity and concentrations of IL-2 in the
bile duct wall were detected by the 𝛽-glucuronidase activity
assay kit (BioVision, USA) and IL-2 rabbit enzyme-linked
immunosorbent assay (ELISA) kit (Jiyinmei Co, Wuhan,
China), respectively, according to themanufacturers’ instruc-
tions. The same method was used to detect the exogenous 𝛽-
G activity in the stones of common bile ducts.
2.6. Statistical Analysis. All data were analyzed using the
SPSS version 19.0 software. Statistical significance was deter-
mined by one-way ANOVA and P value of less than 0.05 is
considered as statistically significant.
3. Results
3.1. Local Gentamicin Infusion Decreases theThickness, Hyper-
plasia Degree of Epithelium, and Submucosal Glands of the
Bile Duct Wall. In the rabbit model, CPC was induced as
papillary hyperplasia in the biliarymucosa, inflammatory cell
infiltration in the bile duct, submucosal glands hyperplasia,
and fibrous thickening in the biliary duct wall. To evaluate
the effects of gentamicin on cholangitis, we examined the
pathological changes in the bile ducts through HE staining.
In the samples analyzed, compared with the PC group
(Figure 1(a)), the hyperplasia degree of epithelium and sub-
mucosal glands of the bile duct wall decreased obviously after
gentamicin treatment (Figure 1(b)). Therefore, we measured
the thickness of the bile duct wall by digital image processing.
The results showed that the thickness of the bile duct wall
in the AT group is less than half of that in the PC group
(P<0.001), though there was still a significant difference
between gentamicin treatment (AT group) and normal values
(SO group) (p<0.001) (Figure 1(d)).
3.2. Inhibition of Cell Proliferation in the Bile Duct by Gentam-
icin Treatment. Subsequently, we examined the expression
level of ki-67 which is a widely used a marker for cell
proliferation by immunohistochemistry. A high percentage
of ki67 expressing cells were observed in the PC group
(Figure 2(a)), which was greatly inhibited by gentamicin
treatment (Figure 2(b)). The data of ki-67 labeling index (LI)
(about 35%, 15%, and 5%, respectively) demonstrated that the
expression level in AT group was significantly lower than that
in the PC group (P<0.001) though it was still higher than that
in the SO group (P<0.001) (Figures 2(c)–2(d)).
3.3. Gentamicin Inhibited the Inflammatory and Lithogenic
Effects in CPC. Both Cox-2 and interleukin 2 (IL-2) play
crucial roles in the process of inflammation [26, 27]. The
expression of the Cox-2 protein, examined by western blot,




























Figure 1: Pathological changes of the common bile duct wall. Hematoxylin-eosin (HE) staining of the common bile duct (original
magnification ×50) showed the hyperplasia of epithelium and submucosal glands of the bile duct wall in positive control group (a) and the
hyperplasia was inhibited by gentamicin in antibiotic treatment group (b), comparedwith those in sham-operation group (c).The thickness of
the bile duct wall was measured (d) and a significant difference was shown between positive control and antibiotic treatment group. (Positive
control versus antibiotic treatment group; antibiotic treatment vs. sham-operation group, p<0.001.)
was only slightly inhibited by gentamicin without significant
difference between the AT and PC group (Figures 3(a)-3(b)).
In contrast, the IL-2 level in the AT group was significantly
decreased compared with that in the PC group (P<0.001),
although slightly higher than that in the SO group (P>0.05)
(Figure 3(c)). Beta-Glucuronidase activity was known as the
key factor in the formation of bile pigment. We detected the
𝛽-G activity of bile ductwall and stones by enzyme colorimet-
ric assay to verify the inhibition of gentamicin on lithogenic
potentiality. A significant decrease of the endogenous𝛽-G
activity was observed after gentamicin treatment (AT versus
PC group, P<0.001; AT vs. SO group, P>0.05). However, this
inhibitory effect was less potent in respect to the exogenous𝛽-
G activity (Figure 3(d)).
4. Discussion
Hepatolithiasis is recognized as an intractable disease because
of the high incidence of stone recurrence and biliary stricture
after surgical resection. However, its etiology is not clear and
there is no effective management to prevent the recurrence.
Targeting CPC in hepatolithiasis has been recently realized
as a novel approach. The intrahepatic stones often injure
the biliary mucosa and result in bacterial infection in the
submucosal layer, as bacteria are present in the bile of all
hepatolithiasis patients. This is the main cause of developing
CPC, characterized by the hyperplasia ofmucosa and submu-
cosal glands and the proliferation of the fibrous connective
tissue. The hyperplastic peribiliary glands and blood vessels
around these glands are usually enclosed or obstructed by the
condensed fibrous connect tissue to form intricate branches.
Thus, bacteria could hide in these branches and cause new
biliary infection which leads to repeated and persistent CPC
[1, 16, 28]. More importantly, the proliferation of fibrous
connective tissue in the bile duct wall could narrow the
biliary lumen to form bile duct strictures, which would slow
the bile flow and lead to bile stasis. Afterwards, bile sludge
could fill in the bile duct and form new pigment stones to
aggravate the hepatolithiasis or cause stone recurrence after
choledochoscopic lithotomy, that is, a vicious cycle between
hepatolithiasis and CPC.
Considering this pathogenic feature, we hypothesize
that inhibition of CPC will be effective in preventing the
stone recurrence and biliary stricture of hepatolithiasis after
choledochoscopic lithotomy. Previous studies have inves-
tigated the antiproliferative effects of cytostatic drugs on
CPC and some inhibition of the hyperplasia of the bil-
iary epithelium, submucosal glands, and collagen fiber in


















Figure 2: Ki67 expression of the common bile duct wall (original magnification ×100). The obvious increase of ki67 expression was
observed in positive control group (a) and only half of that level was observed after gentamicin treatment in the antibiotic treatment group
(b) (antibiotic treatment versus positive control group, P<0.001), which both significantly higher than that in sham-operation group (c).
And the ki67 labeling index (LI) of three groups (d) quantified the difference of ki67 expression among them (about 35%, 15%, and 5%,
respectively).
the bile duct wall has been demonstrated. However, the
cytotoxicity of these drugs was evident, thus limiting the
clinical application [29–32]. As bacterial infection plays a
key role, we have explored antibiotic treatment. In particular,
targeting the Gram-negative bacteria is attractive, as they
are abundantly present in the bile of hepatolithiasis patients
[13].
However, CPC is resistant to routine antibiotics because
of the abnormal structure of the bile duct wall. Classically,
antibiotics reach the bacteria via blood circulation, but it
is inefficient to reach the biliary submucosa and glands
because the blood vessels around these glands are often
stenosed or obstructed in these patients. In these regards, we
believe that local antibiotics infusion, reaching the bacteria
via penetrating the tissue, shall be an effective management
for CPC. Local treatment of gentamicin has been applied
for wound infection, acute conjunctivitis, and urinary tract
stricture in the clinic because of its high tissue penetration
and antibiotic spectrum and being sensitive to most Gram-
negative bacteria. In this study, we applied local gentamicin
infusion in CPC rabbit models and our data showed that
gentamicin effectively inhibited the hyperplasia of the biliary
epithelium, submucosal glands, and collagen fibers in the bile
duct wall. Concurrently, the levels of inflammatory factors
and the endogenous beta-glucuronidase activity, which is
key to pigment stone formation, were decreased by local
gentamicin treatment. Since gentamicin could be injected
via the biliary drainage tube placed after choledochoscopic
lithotomy, we propose that this approach is highly feasible
to be implemented in the clinic to prevent the incidence of
reoperation in hepatolithiasis patients.
In summary, our study has demonstrated the feasibility
and efficacy of local gentamicin infusion for treating CPC in
rabbits. Further studies are warranted to develop into clinical
practice.
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Figure 3:Changes in inflammatory factors in the commonbile duct wall and stones. Cox-2 protein expression in the AT groupwas slightly
decreased by gentamicin treatment comparingwith the positive control group (a), but still significantly higher than that in the sham-operation
group after semiquantified assessment (b) (sham-operation versus antibiotic treatment group, p<0.001). The concentration of IL-2 in the bile
duct in the antibiotic treatment group was inhibited by gentamicin to almost normal (sham-operation versus antibiotic treatment group,
p>0.05), which was significantly lower than that in the positive control group (antibiotic treatment versus positive control group, p<0.001)
(c). The same tendency was observed in the endogenous beta-glucuronidase activity (d).
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